title: [Evaluation of low-dose FP therapy as adjuvant therapy for gastric cancer].
abstract: In the present study, we demonstrate the result of low-dose FP treatment as an adjuvant therapy for 30 patients of stage II or more progressive gastric cancer. 5-FU and CDDP were injected intravenously for 10 days from day 1 through day 5, and day 8 through 12 for 2 weeks at a dose of 250 mg/body and 10 mg/body, or for 14 days at a dose of 250 mg/m2/day and 5 mg/m2/day, respectively. Patients were excluded if they received less than 80% of the respective doses in a course of treatment by the protocol. This constituted a course of chemotherapy, which was repeated every 4 weeks. Grade 3 neutropenia was observed in one case. Other toxicities were anorexia, nausea, weight loss, diarrhea, general fatigue and elevation of serum creatinine, but they were not so severe. The two-year survival rate was 100% in cur A cases, 85% in cur B, and 0% in cur C. The median survival time of the cur C patients was 10 months. These results indicate that low-dose FP therapy is safe and recommendable for cur A and cur B patients. However, other treatment methods such as sequential chemotherapy are needed for cur C gastric cancer patients.
authors.affiliation: Dept. of Gastroenterological and General Surgery, Hokkaido University School of Medicine.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Maeda
authors.forename: Yuji
authors.initials: Y
authors.lastname: Sato
authors.forename: Mitsugu
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Hiroki
authors.initials: H
authors.lastname: Shomura
authors.forename: Shigenori
authors.initials: S
authors.lastname: Honnma
authors.forename: Shigechika
authors.initials: S
authors.lastname: Kohashi
authors.forename: Toshiki
authors.initials: T
authors.lastname: Shinohara
authors.forename: Shusaku
authors.initials: S
authors.lastname: Takahashi
authors.forename: Masao
authors.initials: M
authors.lastname: Kondo
authors.forename: Satoru
authors.initials: S
authors.lastname: Todo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005743:Gastrectomy; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015996:Survival Rate
chemical_list: D002945:Cisplatin; D005472:Fluorouracil